Literature DB >> 33983073

Neuroendocrine carcinoma of the larynx with Lambert-Eaton myasthenic syndrome: a rare case report and literature review.

Massimo Mesolella1, Salvatore Allosso1, Sarah Buono1, Filippo Ricciardiello2, Gaetano Motta3.   

Abstract

This current report describes a rare clinical case of neuroendocrine carcinoma (NEC) of the larynx with associated Lambert-Eaton myasthenic paraneoplastic syndrome (LEMS). A 68-year-old male patient presented with severe dysphonia and dysphagia. He underwent a total laryngectomy and the excised lesion was extremely large. A pathological examination demonstrated 'morphological findings of a poorly differentiated carcinoma (G3) with aspects of neuroendocrine differentiation' (i.e. a poorly differentiated neuroendocrine carcinomas [PD-NEC]). Based on the patient's medical history and the immunohistochemical findings, he was treated with three cycles of neoadjuvant chemotherapy (cisplatin-etoposide) and then radiotherapy with a total dose of 70 Gy. Of the 10 cases of paraneoplastic syndrome (PNS) related to laryngeal NEC reported in the literature, nine of these syndromes were of an endocrine type. Only one case of PNS associated with laryngeal cancer had a neurological manifestation, which was LEMS. To the best of our knowledge, this current case has only one similar precedent in the literature and it is the second report of an association between a PD-NEC and LEMS. Laryngeal NECs are rare lesions with different prognostic characteristics. The diagnosis should be made using an endocrinological, neurological, radiological and histological multidisciplinary approach. A radical surgical approach is recommended.

Entities:  

Keywords:  Lambert-Eaton myastenic syndrome; Neuroendocrine carcinoma; larynx; neurological paraneoplastic syndrome; total laryngectomy

Mesh:

Year:  2021        PMID: 33983073      PMCID: PMC8127768          DOI: 10.1177/03000605211014784

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


Introduction

Neuroendocrine carcinomas (NECs) of the larynx are a varied and heterogeneous tumour of rare observation in clinical practice.[1] This neoplasm of ectodermal origin assumes distinct functional and biological behaviours depending on the location, the size of the overall tumour mass and the histological differentiation.[2] Several classifications and nomenclatures have been developed over the years and to date there are still no clear guidelines regarding the management and therapy of patients.[3,4] The World Health Organization (WHO) classification of 2017 takes into account the histological evaluation and clinical behaviour of neuroendocrine tumours of the larynx, dividing them into: (i) well-differentiated neuroendocrine carcinomas (WD-NEC); (ii) moderately differentiated neuroendocrine carcinomas (MD-NEC); and (iii) poorly differentiated neuroendocrine carcinomas (PD-NEC), which includes (a) small cell neuroendocrine carcinoma (SmCC) and (b) large cell neuroendocrine carcinoma (LCNEC).[5] It is important to acknowledge that the WHO classification, in order to classify the different NECs, also examines in addition to histology and immunohistochemistry for neuroendocrine markers two other parameters that are not used in the NEC of the head and neck district: mitotic activity (expressed in mitosis per 10 high power fields) and proliferative activity (defined as the Ki-67 proliferative index).[5] Well-differentiated neuroendocrine carcinomas or ‘typical carcinoids’ account for approximately 5.27% of laryngeal NECs found.[1,2] Among the neuroendocrine laryngeal neoplasms these are the rarest type. Their presentation is almost exclusively supraglottic.[1-3] MD-NECs or ‘atypical carcinoids’ are the most common type of laryngeal NEC, accounting for 53.7% of laryngeal NECs.[1,6] Their presentation is mostly supraglottic.[1,6] PD-NECs are the second most common type of neuroendocrine carcinomas: 48.6% of the laryngeal NECs found are PD-NEC (more specifically, 41.9% are SmCC and 6.7% are LCNEC). The larynx presentation of this type of tumour is varied.[1-3,6,7] The current case report describes a patient in whom their SmCC was accompanied by Lambert-Eaton myasthenic syndrome (LEMS), a neurological paraneoplastic syndrome (PNS) characterized by proximal muscle weakness and/or autonomic dysfunction caused by self-immunoglobulin G class antibodies directed against voltage-gated type P/Q calcium channels present on the presynaptic cholinergic endings of the neuromuscular plate, decreasing the release of acetylcholine.[8,9] A PNS can sometimes accompany the neoplasm and therefore be useful in monitoring its evolution.[8-11] A diagnosis is achieved by an endocrinological, neurological, radiological and histological multidisciplinary approach. An early diagnosis of a PNS (and its subsequent treatment) can have positive effects on the general clinical outcome, with more appropriate direct therapy on the tumour and an improvement in quality of life.[8-12] Of the 10 PNS related to laryngeal neuroendocrine carcinoma reported in literature, nine of these syndromes were of an endocrine type.[2] In one case, the PNS linked to the laryngeal cancer (an SmCC) had a neurological manifestation, which was LEMS.[2] To the best of our knowledge, this current case has only one similar precedent in the published literature and it is the second report of an association between a PD-NEC and LEMS.

Case report

In October 2017, a 68-year-old male patient presented to the Unit of Otorhinolaryngology, Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy with severe dysphonia and dysphagia during the previous 3 months. Fibrolaryngoscopic examination revealed the presence of a voluminous ulcer-vegetative neoformation that involved the epiglottis, the anterior commissure, the aryepiglottic folds and the tongue base, with a significant reduction in the respiratory space (Figure 1). Blood chemistry tests revealed positivity for carcinoembryonic antigen and tumour antigen 15-3. The patient's clinical history was characterized by poor personal care, marked asthenia, cachexia, marked xerostomia, constipation and urinary retention. The Karnofsky index was 50%. This clinical condition was explained by the fact that the patient lived in a retirement home, he had dysphagia and was suffering from chronic vascular disease.
Figure 1.

Fibrolaryngoscopic examination of a 68-year-old male patient that presented with severe dysphonia and dysphagia during the previous 3 months revealed the presence of a voluminous ulcer-vegetative neoformation that involved the epiglottis, the anterior commissure, the aryepiglottic folds and the tongue base, with a significant reduction in the respiratory space. The colour version of this figure is available at: http://imr.sagepub.com.

Fibrolaryngoscopic examination of a 68-year-old male patient that presented with severe dysphonia and dysphagia during the previous 3 months revealed the presence of a voluminous ulcer-vegetative neoformation that involved the epiglottis, the anterior commissure, the aryepiglottic folds and the tongue base, with a significant reduction in the respiratory space. The colour version of this figure is available at: http://imr.sagepub.com. A total-body computed tomography examination revealed a voluminous expansive neoformation that presented enhancement after contrast into left lateral wall of the larynx. There were also multiple bilateral lymphadenopathies (Figure 2). A laryngeal biopsy revealed ‘morphological findings of poorly differentiated carcinoma (G3) with aspects of neuroendocrine differentiation’ (i.e. PD-NEC). The clinical history and histological examination confirmed the suspicion of associated LEMS. The patient underwent a total laryngectomy with a radical modified neck dissection on the left side with sacrifice of the internal jugular vein and spinal nerve. Selective neck dissection of levels II, III and IV was performed contralaterally. The excised lesion was extremely voluminous (10 cm ×8 cm) (Figure 3).
Figure 2.

Computed tomography examination of a 68-year-old male patient that presented with severe dysphonia and dysphagia during the previous 3 months revealed a voluminous expansive neoformation that presented enhancement after contrast into the left lateral wall of the larynx. There were also multiple bilateral lymphadenopathies.

Figure 3.

A 68-year-old male patient that presented with severe dysphonia and dysphagia during the previous 3 months underwent total laryngectomy. The excised lesion was extremely voluminous (10 cm × 8 cm). The colour version of this figure is available at: http://imr.sagepub.com.

Computed tomography examination of a 68-year-old male patient that presented with severe dysphonia and dysphagia during the previous 3 months revealed a voluminous expansive neoformation that presented enhancement after contrast into the left lateral wall of the larynx. There were also multiple bilateral lymphadenopathies. A 68-year-old male patient that presented with severe dysphonia and dysphagia during the previous 3 months underwent total laryngectomy. The excised lesion was extremely voluminous (10 cm × 8 cm). The colour version of this figure is available at: http://imr.sagepub.com. The postoperative course was uneventful and the patient resumed feeding naturally after approximately 15 days. The histological examination showed a poorly differentiated carcinoma (G3) consisting of small cells with pale cytoplasm, nuclei with finely blotted chromatin and an absence of nucleoli. The immunohistochemical study showed positivity of the neoplastic cells for CK7, synaptophysin and only focal mild positivity for CD56. The results were negative for p40 and p63. The Ki-67 proliferation index was approximately 85%. In the left neck dissection, there were seven lymph nodes infiltrated by carcinoma; and in in the right neck dissection, there were two infiltrated lymph nodes. The patient was treated with three cycles of neoadjuvant chemotherapy using the cisplatinetoposide regimen (130 mg/m2 cisplatin intravenously per day for 3 days and 45 mg/m2 etoposide intravenously per day for 2 days every 3 weeks) and then radiotherapy with a total dose of 70 Gy using a linear accelerator. Approximately 1 month after surgery, a clear improvement in the patient’s condition was recorded. After 3 months, the patient resumed walking without the aid of an orthopaedic walker in addition to there being an improvement in autonomic manifestations (constipation, xerostomia, urinary retention). At 3 years after surgery, the patient is still in follow-up at and is free from disease. The patient’s treatment was conducted in accordance with the Declaration of Helsinki and authorized by the institutional review board committee of Federico II University of Naples, Naples, Italy in accordance with the Italian Association of Oncology 2020 (2017/20331). The authors obtained written consent from the patient to publish this case report.

Discussion

Neuroendocrine carcinomas of the larynx are rare lesions with different prognostic characteristics.[12-14] The most recent WHO classification adequately reflects the genetic and differentiation anomalies underlying the lesions but lacks a correct taxonomy for mixed lesions.[5] Despite the histological similarity of these lesions with other neuroendocrine neoplasms affecting different organs, it is not yet clear whether from the point of view of molecular pathology the laryngeal NECs are identical to the NECs of other organs and whether the NECs of the head and neck district represent a single nosological spectrum or various distinct pathophysiological entities.[12,13] It is important to consider that the clinical behaviour of these lesions differs from laryngeal squamous cell carcinoma (SCC) due to a higher tendency for distant spread and a higher rate of relapse, both loco-regional and distant.[14,15] There are also differences in the optimal therapeutic management as this differs not only between NEC and SCC but also within the various types of NEC.[8-10,12] A radical surgical approach is recommended in WD-NEC and MD-NEC; and in the latter this is accompanied by laterocervical neck dissection as it is possible to develop micrometastases in the early stages of this cancer.[14] The most effective approach to the treatment of these lesions is yet to be determined: currently, it seems that only early and aggressive therapies with a multimodal approach can be considered (Table 1).[1-4,6]
Table 1.

Treatment of paraneoplastic syndrome associated with small cell neuroendocrine carcinoma (SCNC).[1–4,6]

AuthorYearAgeSexParaneoplastic syndromeType of tumourTreatmentFollow-up period and outcome
Trotoux et al.[1]197961MaleSIADHSCNCRadiotherapyDOD 7.7 months
Medina et al.[2]198464FemaleEaton-LambertSCNCChemotherapyDOD 11 months
Bishop et al.[3]198560FemaleACTHSCNCRadiotherapyDOD 0.5 months
Takeuchi et al.[4]198953MaleSIADHSCNCRadiotherapy and surgeryDOD 15 months
Myers and Kessimian[6]199558MaleSIADHSCNCChemotherapyDOD 2 months

SIADH, syndrome of inappropriate secretion of antidiuretic hormone; DOD, dead of disease; ACTH, adrenocorticotropic hormone.

Treatment of paraneoplastic syndrome associated with small cell neuroendocrine carcinoma (SCNC).[1-4,6] SIADH, syndrome of inappropriate secretion of antidiuretic hormone; DOD, dead of disease; ACTH, adrenocorticotropic hormone. Paraneoplastic syndromes related to neuroendocrine carcinomas of the larynx are extremely rare but can cause severe symptoms and almost always correlate with poor prognosis (Table 2).[1-4,6-11] It is debated whether newly diagnosed cases of laryngeal NEC should be screened for one of the PNS already reported in the literature in the 10 existing cases (carcinoid syndrome, syndrome of inappropriate secretion of antidiuretic hormone, Lambert-Eaton, ectopic adrenocorticotropic hormone) (Table 1).[1-4,6]Considering these 10 cases, the estimated incidence of PNS in patients with a laryngeal NEC is approximately 2.3%.[1-4,6] Patients with MD-NEC or PD-NEC (SmCC, 5%) have a higher probability of also having associated PNS, unlike patients with WD-NEC in whom the probability of having NEC-related PNS is lower.[9,11,12] Of the 10 cases of PNS related to laryngeal neuroendocrine carcinoma reported in literature, nine of these syndromes were of an endocrine type (Table 1).[1-4,6] Only one case of PNS linked to laryngeal cancer (an SmCC) had a neurological manifestation, which was LEMS.[2] This current case report presents the second patient with a neurological manifestation in who the laryngeal cancer was first treated with surgery. The previously reported patient that had a neurological manifestation with a laryngeal cancer was treated with two courses of vincristine sulphate, doxorubicin and cyclophosphamide and had a remarkable response for both the primary tumour and the cervical lymph node metastases.[2] Following chemotherapy, the patient was given radiotherapy.[2] The primary tumour received 6095 rad and the neck received 5400 rad [2] At the completion of radiotherapy, there was no evidence of disease in the larynx or the neck.[2] The patient's myasthenic syndrome progressively improved as the treatment of the tumour progressed.[2] After 7 months, the patient received three more courses of chemotherapy.[2] After 7 month, the patient was admitted to the hospital complaining of diplopia. A neurological examination then disclosed dysfunction of the third, fourth and sixth cranial nerves.[2] Her neurological status deteriorated rapidly; seizures developed, she went into a coma, and she died 7 days later.[2]
Table 2.

Paraneoplastic syndrome associated with laryngeal neuroendocrine neoplasms.[1–4,6–11]

Types of tumourAuthorsYearParaneoplastic syndrome
Carcinoid tumourWenig et al.[7]1988Carcinoid
Atypical carcinoid tumourBaugh et al.[8]1986Carcinoid
Overholt et al.[9]1995Carcinoid
Kumai et al.[10]1996Carcinoid
Yamanaka et al.[11]1997Carcinoid
Small cell neuroendocrine carcinomaTrotoux et al.[1]1979Schwartz-Bartter
Medina et al.[2]1984Eaton-Lambert
Bishop et al.[3]1985Cushing
Takeuchi et al.[4]1989Schwartz-Bartter
Myers and Kessimian[6]1995Schwartz-Bartter
ParagangliomaNo reports
Paraneoplastic syndrome associated with laryngeal neuroendocrine neoplasms.[1-4,6-11] Paraneoplastic syndromes are clinical manifestations that reveal the presence of a carcinoma or that appear during its evolution, but have no direct correlation with the tumour or its metastases.[10,12,14] For a large proportion of them, a precise mechanism underlying their development has not yet been identified, but in some cases, PNS are the consequence of an ectopic synthesis of a hormone or a mediator by the tumour, while the structures affected by the symptomatology are not affected by the tumour.[10-15] Neuroendocrine carcinomas of the larynx are rare lesions with different prognostic characteristics. PNS can rarely accompany the neoplasm and therefore be useful in monitoring its evolution. The diagnosis should be made using a multidisciplinary approach.[14-16] An early diagnosis of a PNS and its treatment can have positive effects on the general clinical outcome, with more appropriate direct therapy on the tumour and an improvement in quality of life.[8,9,16,17]
  15 in total

1.  Small cell carcinoma of the larynx and ectopic antidiuretic hormone secretion.

Authors:  T J Myers; N Kessimian
Journal:  Otolaryngol Head Neck Surg       Date:  1995-09       Impact factor: 3.497

2.  Small-Cell Carcinoma of Nasopharynx: A Case Report of Unusual Localization.

Authors:  Massimo Mesolella; Salvatore Allosso; Silvia Varricchio; Daniela Russo; Sara Pignatiello; Sarah Buono; Gaetano Motta
Journal:  Ear Nose Throat J       Date:  2020-12-28       Impact factor: 1.697

3.  Role of perineural invasion as a prognostic factor in laryngeal cancer.

Authors:  Massimo Mesolella; Brigida Iorio; Gabriella Misso; Amalia Luce; Mariano Cimmino; Maurizio Iengo; Mario Landi; Pasquale Sperlongano; Michele Caraglia; Filippo Ricciardiello
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967

4.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What is New in the 2017 WHO Blue Book for Tumours of the Hypopharynx, Larynx, Trachea and Parapharyngeal Space.

Authors:  Nina Gale; Mario Poljak; Nina Zidar
Journal:  Head Neck Pathol       Date:  2017-02-28

Review 5.  Update on Neuroendocrine Carcinomas of the Larynx.

Authors:  Carolina Strosberg; Alfio Ferlito; Asterios Triantafyllou; Douglas R Gnepp; Justin A Bishop; Henrik Hellquist; Primoz Strojan; Stefan M Willems; Göran Stenman; Alessandra Rinaldo; Juan C Hernandez-Prera
Journal:  Am J Clin Pathol       Date:  2019-11-04       Impact factor: 2.493

Review 6.  Moderately differentiated neuroendocrine carcinoma of the larynx. A clinicopathologic study of 54 cases.

Authors:  B M Wenig; V J Hyams; D K Heffner
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

Review 7.  How phenotype guides management of the neuroendocrine carcinomas of the larynx.

Authors:  F López; J L Hunt; I J Nixon; A Rinaldo; M D Williams; A Cardesa; A Ferlito
Journal:  J Laryngol Otol       Date:  2018-06-18       Impact factor: 1.469

8.  Multiple hormone production in an oat cell carcinoma of the larynx.

Authors:  J W Bishop; R Y Osamura; Y Tsutsumi
Journal:  Acta Pathol Jpn       Date:  1985-07

9.  Neuroendocrine neoplasms of the larynx.

Authors:  S M Overholt; D T Donovan; M R Schwartz; R Laucirica; L K Green; B R Alford
Journal:  Laryngoscope       Date:  1995-08       Impact factor: 3.325

10.  Overexpression of chromatin assembly factor-1/p60 predicts biological behaviour of laryngeal carcinomas.

Authors:  M Mesolella; B Iorio; M Landi; M Cimmino; G Ilardi; M Iengo; M Mascolo
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-02       Impact factor: 2.124

View more
  1 in total

1.  Clinical characteristics of paraneoplastic syndromes in patients with head and neck cancer.

Authors:  Wenwen Diao; Ya Liang; Liming Gao; Yingying Zhu; Xiaoli Zhu; Shuting Yu; Xin Xia; Xingming Chen
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-07-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.